Diagnostic imaging and therapeutic agents to help identify and treat disease and improve patient care
Improved diagnostic information for better patient management
Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.
Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent
PyL™ (18F-DCFPyL), Lantheus’ PSMA-Targeted Prostate Cancer Imaging Agent, to be Used in POINT Biopharma’s PSMA-Targeted Radioligand Therapeutic Phase 3 Trial in Patients with Metastatic Castration Resistant Prostate Cancer
Providing you with important information regarding our response to the C0VID-19 pandemic.
(updated 1/8/2020)
View a Lantheus webinar:
COVID-19: Clinical Experiences from the Front Line in NYC
Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.
Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent
PyL™ (18F-DCFPyL), Lantheus’ PSMA-Targeted Prostate Cancer Imaging Agent, to be Used in POINT Biopharma’s PSMA-Targeted Radioligand Therapeutic Phase 3 Trial in Patients with Metastatic Castration Resistant Prostate Cancer
At Lantheus, we develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.
We are developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.